FDA Grants Genentech ’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

South San Francisco, CA -- March 8, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab) plus...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news